当前位置: X-MOL 学术J. Natl. Cancer Inst. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2017-11-21 , DOI: 10.1093/jnci/djx241
Yazid Belkacemi 1 , Abraham Kuten 2
Affiliation  

We congratulate Gingras et al. for their report on regional node irradiation (RNI) in the human epidermal growth factor receptor 2 (HER2)–targeted therapy era (1). They suggest that RNI has no impact on disease-free survival (DFS) in node-positive (N+), HER2-positive breast cancer (BC) patients treated with conservative surgery, axillary node dissection (ALND), and whole breast irradiation. These results reported in the anti-HER2 era contradict RNI data from the MA20 and EORTC22922 trials (2,3).

中文翻译:

RE:早期HER2阳性乳腺癌的保乳手术后的局部淋巴结照射:ALTTO试验的亚分析结果

我们祝贺Gingras等人。他们关于人类表皮生长因子受体2(HER2)靶向治疗时代的区域淋巴结照射(RNI)的报告(1)。他们认为,RNI对结节阳性(N +),HER2阳性乳腺癌(BC)接受保守手术,腋窝淋巴结清扫(ALND)和全乳照射的患者的无病生存期(DFS)没有影响。抗HER2时代报道的这些结果与MA20和EORTC22922试验的RNI数据相矛盾(2,3)。
更新日期:2017-11-21
down
wechat
bug